Advertisement

Zusammenfassung

Ulzera können mit Antacida wirksam behandelt werden. Die Effektivität der Antacida läßt sich nicht allein durch ihre Säureneutralisationskapazität erklären, da schon sehr niedrige Dosierungen mit einer Neutralisationskapazität von 100=200 mmol/Tag Ulzera zur Abheilung bringen. Diskutiert wird auch, inwieweit säureunabhängige Faktoren wie Gallensäuren, der plättchenaktivierende Faktor, exogene Noxen (Crack) und Helicobacter pylori an der Genese des Ulcus ventriculi beteiligt sind und welchen Einfluß Antacida auf diese aggressiven Faktoren haben.

How effective are antacids in the treatment of gastric ulcer?

Abstract

Antacids are effective therapeutic agents in peptic ulcers. The efficacy of antacids cannot be explained by the acid neutralization capacity only because very low dosages with a daily neutralization capacity of 100-200 ml are already effective.

Other factors are also discussed which may play an active role in ulcer-disease, such as bile acids, Helicobacter pylori, PAF and Crack, as well as how antacids may influence these acid-independant factors.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literaturverzeichnis

  1. 1.
    Abramson DL, Gertler JP, Lewis T, Gral JG. Crack-related perforated gastropyloric ulcer. J Clin Gastroenterol 1991; 13: 17–19.PubMedCrossRefGoogle Scholar
  2. 2.
    Aceti A, Celestino D, Caferro M, Casale V, Citarda F, Conti EM et al. Basophilbound and serum immunoglobulin E directed against Helicobacter pylori in patients with chronic gastritis. Gastroenterology 1991; 101: 131–137.PubMedGoogle Scholar
  3. 3.
    Bezuidenhout DJJ, Perold JG, Adams G. A comparison of 4-week peptic ulcer healing rates following treatment with antacids and ranitidine. S Afr Med J 1984; 65: 1007–1009.PubMedGoogle Scholar
  4. 4.
    Black RB, Hole D Rhodes Jw. Bile damage to the gastric mucosal barrier: the influence of pH and bile acid concentration. Gastroenterology 1971; 61: 178–184.PubMedGoogle Scholar
  5. 5.
    Blum AL. Stellung der Antazida in der modernen Ulkustherapie. Dtsch Med Wochenschr 1985; 110: 3–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Bosseckert H, Fuckel R, Winnefeld K. Gallegehalt im Magensaft bei Magenerkrankungen. Noch nicht veröffentlicht.Google Scholar
  7. 7.
    Brackmann H-P. Physiologisch-logische Wirkprinzipien in der Ulkustherapie. Therapiewoche 1985; 35: 4007–4023.Google Scholar
  8. 8.
    Brzozowski T, Majka J, Garlicki J, Drozdowicz D, Konturek S. Role of polyamines and prostaglandins in gastroprotective action of epidermal growth factor against ethanol injury. J Clin Gastroenterol 1991; 13 (Suppl 1): 98–100.CrossRefGoogle Scholar
  9. 9.
    Bugnoli M, Armellini D, Figura N, Rossolini A. The 130 kDa vacuolizing cytotoxinassociated protein is a component of cytotoxic Helicobacter pylori organisms. Ital J Gastroenterol 1991; 23 (Suppl 2): 37.Google Scholar
  10. 10.
    Butler ML Gersh H. Antacid vs placebo in hospitalized gastric ulcer patients: A controlled therapeutic study. Am J Dig Dis 1975; 20: 803–807.PubMedCrossRefGoogle Scholar
  11. 11.
    Caspary WF, Graf S. Bindung von Gallensäuren an Antazida. Dtsch Med Wochenschr 1978; 103: 825–827.PubMedCrossRefGoogle Scholar
  12. 12.
    Chan WY, Hui PK, Chan JKC, Cheung PSY, NG CS, Sham CH. Epithelial damage by Helicobacter pylori in gastric ulcers. Histopathology 1991; 19: 47–53.PubMedCrossRefGoogle Scholar
  13. 13.
    Clemencon GH. Der duodenogastrische Reflux—endoskopische Diagnose. Akt Gastrol 1979; 8: 461–470.Google Scholar
  14. 14.
    Crabtree JE, Taylor JD, Wyatt JI, Shallcross TM, Heatley RV, Tompkins DS et al. Mucosal IgA recognition of Helicobacter pylori 120 kDa protein, peptic ulcers and gastric pathology. Ital J Gastroenterol 1991; 23 (Suppl 2): 51.Google Scholar
  15. 15.
    Davenport HW. Destruction of the gastric mucosal barrier by detergents and urea. Gastroenterology 1968; 54: 175–181.PubMedGoogle Scholar
  16. 16.
    Daw MA, Keane CT, Moore RO, Morain CO. Phospholipase C activity: new pathogenicity marker for Helicobacter pylori. Ital J Gastroenterol 1991; 23 (Suppl 2): 37–38.Google Scholar
  17. 17.
    Denizot Y, Sobhani J, Rambaud JC, Lewin M, Thomas Y, Benveniste J. Paf-acether synthesis by Helicobacter pylori. Gut 1990; 31: 1242–1245.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Eastwood GL. Effect of pH on bile salt injury to mouse gastric mucosa. A light- and electron-microscopic study. Gastroenterology 1975; 68: 1456–1465.PubMedGoogle Scholar
  19. 19.
    Englert E JR, Freston JW, Graham DY et al. Cimetidine, antacid and hospitalization in the treatment of benign gastric ulcer. A multicenter double-blind study. Gastroenterology 1978; 74: 416–425.PubMedGoogle Scholar
  20. 20.
    Flemstrom G, Turnberg LA. Gastroduodenal defence mechanisms. Clin Gastroenterol 1984; 13: 327–354.PubMedGoogle Scholar
  21. 21.
    Fordtran JS, Stephan G, Morawski BA, Richardson CT. In vivo and in vitro evaluation of liquid antacids. N Engl J Med 1973; 288: 923–928.PubMedCrossRefGoogle Scholar
  22. 22.
    Gough KR. Klinische Erfahrungen mit der Langzeittherapie: Sicherheit und Nebenwirkungen. Res Clin Forum 1989; 10: 85–91.Google Scholar
  23. 23.
    Hazell SC. Urease and Catalase as virulence factor of Helicobacter pylori. In: Menge H, Gregor M, Tytgat GNJ, Marshall BJ, McNulty CAM (eds.). Helicobacter pylori 1990. Springer 1991: 3–12.CrossRefGoogle Scholar
  24. 24.
    Hollander D, Harlom J. Antacids vs placebo in peptic ulcer therapy. J Am Med Wom Assoc 1973; 226: 1181–1183.CrossRefGoogle Scholar
  25. 25.
    Holzer P, Pabst MA, Lippe JT. Intragastric Capsaicin protects against aspirin-induced lesion formations and bleeding in the rat gastric mucosa. Gastroenterology 1989; 96: 1425–1433.PubMedGoogle Scholar
  26. 26.
    Isenberg JI, Peterson WL, Elashoff JD et al. Healing of benign gastric ulcer with lowdose antacid or cimetidine. A double-blind, randomized, placebo-controlled trial. N Eng! J Med 1983; 308: 1319–1324.CrossRefGoogle Scholar
  27. 27.
    Ivey KJ, Denbesten L, Clifton JA. Effect of bile salts On ionic movement across the human gastric mucosa. Gastroenterology 1970; 59: 683–690.PubMedGoogle Scholar
  28. 28.
    Ivey KJ. Gastric mucosal barrier. Gastroenterology 1971; 61: 247–257.PubMedGoogle Scholar
  29. 29.
    Kurose I, Suetmatso M, Miura S, Suzuki M, Nagata H, Morishita T et al. Involvement of superoxide anion and platelet — activating factor in increased tissue-type plasminogen activator during rat gastric microvascular damages. Thromb Res 1991; 62: 241–248.PubMedCrossRefGoogle Scholar
  30. 30.
    Kurtz W, Güldütuna S, Leuschner U. Einfluß von pH und Antazidummenge auf die Gallensäuren-Bindung in quasinatürlichem Refluxmilieu. Z Gastroenterol 1991; 29: 237–241.PubMedGoogle Scholar
  31. 31.
    Lanza FL, Sibley CM. Role of antacids in the management of disorders of the upper gastrointestinal tract. Rev Clin Exp 1975–1985.Google Scholar
  32. 32.
    Lingwood CA, Law H, Pellizzari A, Sherman P, Drumm B. Gastric glycerolipid as a receptor of Campylobacter pylori. Lancet 1989; II: 238–241.CrossRefGoogle Scholar
  33. 33.
    Littman A, Welch R, Fruin RC, Aronson AR. Controlled trials of aluminium hydroxyde gels for peptic ulcer. Gastroenterology 1977; 73: 6–10.PubMedGoogle Scholar
  34. 34.
    Lopez Lavid C, Sanz JC, Martin E, Castanos R, Junenez J, Lopez-brea M. Helicobacter pylori: Biotypes and correlation with antimicrobial susceptibility. Rev Esp Enferm Apar Dig 1990; 78 (Suppl 1): 94.Google Scholar
  35. 35.
    Miederer SE, Mayershofer R, LÖFfler A. Magaldrat (100 mmol/d) gegen Ranitidin (300 mg/d). Med Klin 1986; 81: 162–165.Google Scholar
  36. 36.
    Miyake T, Ariyoshi J, Suzaki T et al. Endoscopic evaluation of the effect of sucralfate therapy and other clinical parameters on the recurrence rate of gastric ulcers. Dig Dis Sci 1980;25: 1–7.PubMedCrossRefGoogle Scholar
  37. 37.
    Mooney C, Keenan J, Munster D, Wilson J, Allardyce R, Bagshaw B et al. Neutrophil activation by Helicobacter pylori. Gut 1991; 32: 833–837.CrossRefGoogle Scholar
  38. 38.
    Morgan AG, Pacsoo C, Mcadam Waf. Maintenance therapy: A two-year comparison between Caved-S and cimetidine treatment in the prevention of symptomatic gastric ulcer recurrence. Gut 1985; 26: 599–602.PubMedCentralPubMedCrossRefGoogle Scholar
  39. 39.
    Nagy L, Mozsik GY, Vincze A, Süto G, Hunyady B, Rinfel J et al. Effects of a novel hungarian antacid combining Al and Mg (Tisacid) on mucosal prostaglandin generation and oxygen free radicals in normal rat. Drugs Exp Clin Res 1990; 16: 197–203.PubMedGoogle Scholar
  40. 40.
    Negrini R, Lisato L, Zanella J, Cavazzini L, Gullini S, Villanacci V et al. Helicobacter pylori infection induces antibodies cross-reacting with human gastric mucosa. Gastroenterology 1991; 101: 437–445.PubMedGoogle Scholar
  41. 41.
    Pace F, Broker HJ, Domschke W et al. Treatment of gastric ulcer with low-dose antacid gel and cimetidine: A multi-centre double-blind trial. Dtsch Med Wochenschr 1985; 110: 283–287.PubMedCrossRefGoogle Scholar
  42. 42.
    Pace F, Bröker H-J, Caspary W, Domschke W, Feurle G, Fimmel CJ et al. Therapie des Ulcus ventriculi mit niedrig dosiertem Antacidumgel und Cimetidin. Dtsch Med Wochenschr 1985; 110: 283–287.PubMedCrossRefGoogle Scholar
  43. 43.
    Rio MC, Chenard MP, Wolf C, Marcellin L, Tomasetto C, Lathe R et al. Induction of pS2 and USP Genes as markers of mucosal ulceration of the digestive tract. Gastroenterology 1991; 100: 375–379.PubMedGoogle Scholar
  44. 44.
    Sherbaniuk RW, Wensel RH, Bailey RJ et al. Comparative study of cimetidine and Mylanta-II in the 6-week treatment of gastric ulcer. J Clin Gastroenterol 1985; 7: 211–215.PubMedCrossRefGoogle Scholar
  45. 45.
    Sipponen P, SeppäLä K, äärginen M, Helske T, Kettunen P. Chronic gastritis and gastroduodenal ulcer: a case control study on risk of coexisting duodenal or gastric ulcer in patients with gastritis. Gut 1989; 30: 922–929.PubMedCentralPubMedCrossRefGoogle Scholar
  46. 46.
    Szelenyi J. Mukosabarriere — Schutz durch Prostaglandine. Z Allg Med 1984; 60: 1306–1314.Google Scholar
  47. 47.
    Vergin H, Kori-Lindner C. Rutative mechanisms of cytoprotective effect of certain antacids and sucralfate. Dig Dis Sci 1990; 35: 1320–1327.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Fachmedien Wiesbaden 1992

Authors and Affiliations

  • H. Bosseckert
    • 1
  1. 1.Klinik für Innere MedizinFriedrich-Schiller-UniversitätJenaDeutschland

Personalised recommendations